Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...
Discusses Phase II Acute Graft Versus Host Disease and Phase III Osteoarthritis Trial Results June 21, 2026 6:30 ...
When Is the Right Time? A Qualitative Study of Timing of Specialty Palliative Care in Patients With Brain Tumors Phase II trials are intended to identify promising treatment paradigms for definitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results